WUXAY WuXi AppTec Co Ltd ADR Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
22:19
Aug 04
Aug 04
Strong earnings and irreplaceable position in GLP-1.
WuXi AppTec reported a 20% earnings beat for Q2, driven by strong growth in its CMO and CDMO businesses. The company holds a 25% market share in the global GLP-1 (obesity) drug supply chain, and its US revenue portion has increased to 77% despite US sanctions, demonstrating its irreplaceable market position.
HIGH
05:01
Aug 04
Aug 04
WuXi AppTec booms on obesity drug demand
WuXi AppTec delivered a very strong earnings beat driven by surging obesity drug demand from both oral and injectable GLP-1. Raised capex guidance indicates robust future demand. Despite geopolitical noise and potential generic competition, pricing is already very affordable, and the company continues to deliver essential scale and quality that global pharma depends on.
HIGH
13:30
Aug 03
Aug 03
WuXi AppTec states that its placement on the Pentagon's Chinese military-linked list creates.
WuXi AppTec states that its placement on the Pentagon's Chinese military-linked list creates uncertainty for its critical US business operations.
About WUXAY Analyst Coverage
Buzzberg tracks WUXAY (WuXi AppTec Co Ltd ADR) across 3 sources. 2 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (67%). 3 total trade ideas tracked. Past 7 days: 2 bullish, 1 watch. Latest voices: Wang, Cui Cui, Bloomberg.